Jerry Shapiro

InstitutionNew York University School of Medicine
AddressNew York
New York
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 9 Covid-19 publications, with a maximum of 2 publications in April 2020 and August 2021
    All Publications
    Bar chart showing 108 publications over 19 distinct years, with a maximum of 11 publications in 2018
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Starace M, Iorizzo M, Sechi A, Alessandrini AM, Carpanese M, Bruni F, Vara G, Apalla Z, Asz-Sigall D, Barruscotti S, Camacho F, Doche I, Estrada BD, Dhurat R, Gavazzoni MF, Grimalt R, Harries M, Ioannidis D, McMichael A, Melo DF, Oliveira R, Ovcharenko Y, Pirmez R, Ramot Y, Rudnicka L, Shapiro J, Silyuk T, Sinclair R, Tosti A, Vano-Galvan S, Piraccini BM. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021 Dec; 5:11-18. PMID: 34368790.
      Citations:    
    2. Shaw KS, Yin L, Shah JK, Sally RA, Svigos KS, Adotama PU, Tuan HH, Shapiro J, Betensky RA, Lo Siccoa KI. COVID-19 in Individuals Treated With Long-Term Hydroxychloroquine: A Propensity Score-Matched Analysis of Cicatricial Alopecia Patients. J Drugs Dermatol. 2021 Aug 01; 20(8):914-916. PMID: 34397203.
      Citations:    Fields:    Translation:HumansPHPublic Health
    3. McCoy J, Goren A, Cadegiani FA, Vaño-Galván S, Kovacevic M, Situm M, Shapiro J, Sinclair R, Tosti A, Stanimirovic A, Fonseca D, Dorner E, Onety DC, Zimerman RA, Wambier CG. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021; 8:668698. PMID: 34350193.
      Citations: 6     
    4. Cadegiani FA, McCoy J, Gustavo Wambier C, Vaño-Galván S, Shapiro J, Tosti A, Zimerman RA, Goren A. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021 Feb 22; 13(2):e13492. PMID: 33633920.
      Citations: 15     
    5. Goren A, Cadegiani FA, Wambier CG, Vano-Galvan S, Tosti A, Shapiro J, Mesinkovska NA, Ramos PM, Sinclair R, Lupi O, Hercogova J, McCoy J. Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 01; 146:110439. PMID: 33308937.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    6. McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Sinclair R, Ramos PM, Washenik K, Andrade M, Herrera S, Goren A. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul; 19(7):1542-1543. PMID: 32333494.
      Citations: 33     Fields:    Translation:HumansPHPublic Health
    7. Wambier CG, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard Á, Moreno-Arrones OM, Jiménez-Gómez N, González-Cantero A, Fonda-Pascual P, Segurado-Miravalles G, Shapiro J, Pérez-García B, Goren A. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug; 83(2):680-682. PMID: 32446821.
      Citations: 39     Fields:    Translation:HumansCellsPHPublic Health
    8. Goren A, Vaño-Galván S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair RD, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M, Washenik K. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul; 19(7):1545-1547. PMID: 32301221.
      Citations: 56     Fields:    Translation:HumansPHPublic Health
    9. Goren A, McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Dhurat R, Washenik K, Lotti T. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul; 33(4):e13365. PMID: 32237190.
      Citations: 17     Fields:    Translation:HumansAnimalsPHPublic Health